By the Peptevity Research Desk — vendor-neutral, evidence-graded. Scientific review: independent reviewer pending — how our review works.

GHK-Cu (Copper Peptide): An Evidence-Graded Monograph

Direct answer

GHK-Cu is the copper(II) complex of the human tripeptide glycyl-L-histidyl-L-lysine — a fragment that occurs naturally in blood plasma, where levels fall from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60 (Pickart & Margolina, 2018, PMC6073405). The strongest human evidence is topical and cosmetic: small controlled facial trials reported improvements in skin density, fine lines, and clarity (Grade B) (Pickart & Margolina, 2018, PMC6073405). Claims about wound healing and systemic anti-aging rest mainly on rodent and cell-culture work — animal/in-vitro only, no human RCTs (Grade C–D) (PMC6073405; Dou et al., 2020, PMC8789089). As of June 2026, GHK-Cu is not an FDA-approved drug; topical copper-peptide cosmetics are permitted as a cosmetic ingredient, while injectable material is sold "research use only," and its 503A compounding status is under active FDA review, with a Pharmacy Compounding Advisory Committee consultation expected before the end of February 2027.

What GHK-Cu is

GHK is a short tripeptide — three amino acids, glycine–histidine–lysine — first isolated by biochemist Loren Pickart in the 1970s from human plasma. The molecule has a high binding affinity for copper(II) ions, and when it chelates copper it forms the complex written GHK-Cu (cosmetic ingredient name: copper tripeptide-1) (Pickart & Margolina, 2018, PMC6073405). The peptide is endogenous: it circulates in human serum and is thought to be released locally when tissue is injured.

A frequently cited observation is that plasma GHK declines with age — about 200 ng/mL at 20, falling to roughly 80 ng/mL by 60 (Pickart & Margolina, 2018, PMC6073405). The decline is real and measured. On its own, though, it is a correlation, not proof that replacing GHK reverses any aging process — a distinction the popular literature routinely blurs.

Two delivery routes dominate, and they are not regulatory or evidentiary equals:

  • Topical — copper-peptide creams and serums, regulated as cosmetics. This is where the human data sits.
  • Injectable / systemic — research-grade lyophilized GHK-Cu sold "research use only." Human outcome trials for this route are effectively absent; the case rests on animal and cell studies.

Throughout this monograph we keep those lanes separate. For how Peptevity assigns the letter grades below, see our evidence-grading methodology.

Mechanism of action (Grade D — mechanistic / in-vitro)

The proposed mechanisms are interesting biochemistry. Almost all of them, though, are demonstrated in cell culture or by gene-expression profiling — not in human outcomes. We grade the mechanism claims D (in-vitro / mechanistic) even where the downstream skin claims earn a higher grade.

  • Copper delivery and redox quieting. Copper is a cofactor for connective-tissue enzymes such as lysyl oxidase. By chelating copper(II), GHK is proposed to deliver the ion in a bioavailable form while limiting its free-radical (Fenton) reactivity (Pickart & Margolina, 2018, PMC6073405).
  • Extracellular-matrix synthesis. In cultured fibroblasts, GHK-Cu stimulates proliferation and upregulates genes for collagen, elastin, dermatan sulfate, chondroitin sulfate, and decorin, while modulating matrix metalloproteinases (MMPs) and their inhibitors toward balanced remodeling (Pickart & Margolina, 2018, PMC6073405).
  • Angiogenic and growth-factor signaling. In irradiated human dermal fibroblasts, GHK-Cu (around 1 nM) increased expression of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) (Dou et al., 2020, PMC8789089).
  • Broad gene-expression modulation. The most-quoted figure — that GHK "resets" thousands of genes — comes from the Broad Institute's Connectivity Map dataset. In that analysis, GHK changed expression of a large fraction of assayed human genes by ≥50% (the authors report roughly 31.2% of genes meeting that threshold, increasing expression in about 59% and suppressing it in about 41% of affected genes) (Pickart & Margolina, 2018, PMC6073405). This is a striking in-vitro signal that is often inflated online into the claim that GHK "regulates 4,000+ genes" in people. It is cell-line transcriptomics, not a clinical outcome.
  • Antioxidant / anti-inflammatory signaling. In cell models, GHK and GHK-Cu reduced reactive oxygen species and suppressed pro-inflammatory cytokines (TNF-α, IL-6) via NF-κB (p65) and p38 MAPK pathways (Dou et al., 2020, PMC8789089).

So the mechanistic story is rich and biologically plausible. It explains why researchers expected topical benefit. What it does not do, on its own, is demonstrate benefit in a living person.

The evidence, by claim and species

Skin / cosmetic anti-aging — Grade B (limited human evidence)

This is the only domain where GHK-Cu has direct human trial support, and even here the trials are small, mostly industry-associated, and decades old.

  • Facial photoaging. A 12-week study applied a GHK-Cu facial cream to 71 women with mild-to-advanced photoaging and reported increased skin density and thickness, reduced laxity, improved clarity, and reduced fine lines and wrinkle depth (Pickart & Margolina, 2018, PMC6073405).
  • Periorbital (eye-area) skin. A companion 12-week trial in 41 women with photoaged eye-area skin reported a GHK-Cu eye cream outperformed both a placebo and a vitamin-K cream for reducing periorbital lines and improving skin density (Pickart & Margolina, 2018, PMC6073405).
  • Wrinkle volume. A double-blind comparison reported a GHK-Cu product produced roughly a 31.6% reduction in wrinkle volume versus a comparator (Pickart & Margolina, 2018, PMC6073405).

Why B, not A: these are small samples (tens of participants), several were sponsor-linked, endpoints relied on profilometry/ultrasound rather than hard clinical outcomes, and the work has not been replicated in large, independent randomized controlled trials. The direction of evidence is real and it is human — which is exactly what separates a B from the animal-only claims below. We say "limited human data supports a cosmetic effect," not "GHK-Cu rejuvenates skin." A broader 2026 systematic review and meta-analysis of topical and oral peptides for skin aging contextualizes how thin the high-quality RCT base remains across the whole peptide category (Frontiers in Medicine, 2026).

Wound healing — Grade C (animal-only)

The "wound healing" reputation is built almost entirely on animal models. There are no qualifying human wound-healing RCTs in the cited reviews.

These are consistent animal findings, robust in places. They are still Grade C. Studies in rats and rabbits suggest faster collagen deposition; that does not establish that injected or applied GHK-Cu heals human wounds, and we will not state it as if it did.

Longevity / systemic anti-aging — Grade C–D (animal and mechanistic)

Here is where online claims run furthest ahead of the evidence. The systemic "anti-aging" case is animal- and cell-based.

  • Lung injury (mice). GHK-Cu protected mouse lung tissue from induced acute lung injury, raised superoxide dismutase activity, and suppressed TNF-α/IL-6 in LPS models (Pickart & Margolina, 2018, PMC6073405).
  • Cognition (aged mice). In 28-month-old mice given GHK at 10 mg/kg (5×/week for 3 weeks), treated animals showed improved learning, with brain tissue showing less inflammation (Dou et al., 2020, PMC8789089).
  • Pain / anxiety (rats). Animal models report analgesic and anxiolytic-type effects (Pickart & Margolina, 2018, PMC6073405).
  • Clotting (mechanistic). GHK strongly downregulates the gene for the beta chain of fibrinogen in cell data — a finding sometimes cited as a benefit, but it also flags a plausible effect on coagulation that has not been characterized in humans (Pickart & Margolina, 2018, PMC6073405).

There are no human longevity or systemic-outcome trials for GHK-Cu in the reviews we rely on. The "reverses aging at the DNA level" framing circulating in vendor and influencer content is a Grade D mechanistic signal dressed up as a Grade A outcome. We grade it as what it is.

Safety

Safety and evidence grade are separate axes (see our evidence-grading methodology); a topical with reasonable safety data can still have an unstudied injectable lane.

  • Topical / cosmetic. The Cosmetic Ingredient Review panel assessed copper tripeptide-1 and concluded it is safe as used in cosmetics, noting low use concentrations (typically <10 ppm in finished products) such that the low concentrations and negative safety-test data "obviate any concerns" about its cosmetic use (CIR, 2018). Reported topical reactions are generally mild and local — redness or irritation — consistent with the panel's negative skin-sensitization data.
  • Long-term and systemic safety — largely unstudied. No published human trials characterize long-term systemic or injectable use; the systemic case rests principally on animal and in-vitro work (Pickart & Margolina, 2018, PMC6073405; Dou et al., 2020, PMC8789089). Reviews describing decades of "use without adverse effects" refer to cosmetic use; that is not the same as safety data for injection (Pickart & Margolina, 2018, PMC6073405).
  • Plausible cautions, not scare warnings. Because copper is biologically active, individuals with copper-metabolism disorders (e.g., Wilson's disease) are a reasonable population to flag for clinician oversight; on the Cleveland Clinic Wilson disease overview copper handling is the core problem. The mechanistic fibrinogen finding above also argues for not assuming the injectable route is consequence-free.

We do not issue a blanket "just don't." We state the specific, sourced picture: topical copper peptide has a reasonable cosmetic-safety record; the systemic/injectable route is essentially uncharacterized in humans.

The standing Regulatory status block above carries the dated summary; this section explains the nuance, because GHK-Cu sits across multiple regulatory lanes at once.

  • It is not an FDA-approved drug. No GHK-Cu product is approved to treat, cure, or prevent any condition. Vendor pages making such claims are making unapproved drug claims.
  • Topical = cosmetic lane. As copper tripeptide-1, it is a legal cosmetic ingredient in over-the-counter skincare; the FDA does not pre-approve cosmetic ingredients, and CIR has reviewed it as safe-as-used (CIR, 2018).
  • Injectable/compounding = volatile lane. GHK-Cu has moved across FDA's interim 503A bulk drug substances categories. On 2026-04-15 the FDA announced it was removing GHK-Cu — non-injectable routes from Category 1, injectable routes from Category 2 — because the original nominations were withdrawn, which is explicitly not a finding that it is safe to compound. GHK-Cu sits in the second of two peptide review groups, with a Pharmacy Compounding Advisory Committee consultation expected before the end of February 2027 (the July 23–24, 2026 PCAC hearing covers a different group: BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and epitalon). The compounding pathway is therefore unsettled and under active review, not affirmatively open (FDA — 503A bulks).
  • Research-grade = "RUO." Injectable GHK-Cu sold online is labeled "research use only — not for human consumption." That label is a legal category, not a wink. For the broader framing, see our note on what "research use only" means and whether peptides are legal.

Because this lane shifts, the date matters. We review this page on the same cadence as our living 2026 regulatory tracker; if the PCAC review changes the status, this monograph is updated and the change is logged under our corrections policy.

Honest bottom line

GHK-Cu is one of the better-characterized peptides on the cosmetic side and one of the most over-claimed on the systemic side. Topical copper-peptide skincare has limited but genuine human evidence (Grade B) for modest improvements in photoaged skin, plus a reasonable cosmetic-safety record. Wound healing is animal-only (Grade C); systemic "longevity" and "DNA-level rejuvenation" claims are animal and cell-culture signals (Grade C–D) with no human outcome trials behind them. It is not an FDA-approved drug; the topical cosmetic lane is permitted, while the injectable lane is research-use-only and its compounding status is under active FDA review as of June 2026. If you read one thing into this page, read the gap between the well-supported topical story and the speculative systemic one — and treat the marketing that collapses the two as exactly that.

For neighboring compounds where the same animal-vs-human gap appears, compare our monographs on the healing peptide BPC-157 and the tissue-repair peptide TB-500, and see the category overview of peptides for health and longevity. For the safety framing across the catalog, see are peptides safe.

How we graded this page

Every claim above is tied to its strongest primary source and labeled by species, per our evidence-grading methodology and sourcing and citation policy. Peptevity carries no advertising, no affiliate links, and sells nothing — see our conflict-of-interest and funding statement.

Primary sources

  • Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMC6073405
  • Dou Y, Lee A, Zhu L, Morton J, Ladiges W. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 2020;2(1):58–61. PMC8789089
  • Cosmetic Ingredient Review. Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives. 2018. CIR PDF
  • U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A. FDA
  • Oral and topical peptides for skin aging: systematic review and meta-analysis of RCTs. Front Med. 2026. Frontiers

External references appear as citations only; none of the cited institutions endorse, review, or are affiliated with Peptevity.

Every claim above is cited inline to a primary source. See how we grade evidence and our sourcing & citation policy.